Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma

Ryan D. Morin(BC Cancer Agency), María Méndez-Lago(BC Cancer Agency), Andrew J. Mungall(BC Cancer Agency), Rodrigo Goya(Canada's Michael Smith Genome Sciences Centre), Karen Mungall(BC Cancer Agency), Richard Corbett(BC Cancer Agency), Nathalie A. Johnson(BC Cancer Agency), Tesa Severson(BC Cancer Agency), Readman Chiu(BC Cancer Agency), Matthew A. Field(Canada's Michael Smith Genome Sciences Centre), Shaun D. Jackman(Canada's Michael Smith Genome Sciences Centre), Martin Krzywinski(BC Cancer Agency), David W. Scott(BC Cancer Agency), Diane L. Trinh(Canada's Michael Smith Genome Sciences Centre), Jessica Tamura‐Wells(BC Cancer Agency), Sa Li(BC Cancer Agency), Marlo Firme(BC Cancer Agency), Sanja Rogić(BC Cancer Agency), Malachi Griffith(BC Cancer Agency), Susanna Chan(Canada's Michael Smith Genome Sciences Centre), Oleksandr Yakovenko(Canada's Michael Smith Genome Sciences Centre), Irmtraud M. Meyer, Eric Y. Stutheit-Zhao(BC Cancer Agency), Duane E. Smailus(BC Cancer Agency), Michelle Moksa(Canada's Michael Smith Genome Sciences Centre), Suganthi Chittaranjan(Canada's Michael Smith Genome Sciences Centre), Lisa M. Rimsza(University of Arizona), Angela Brooks‐Wilson(BC Cancer Agency), John J. Spinelli(University of British Columbia), Susana Ben‐Neriah(BC Cancer Agency), Barbara Meissner(BC Cancer Agency), Bruce W. Woolcock(BC Cancer Agency), Merrill Boyle(BC Cancer Agency), Helen McDonald(Canada's Michael Smith Genome Sciences Centre), Angela Tam(Canada's Michael Smith Genome Sciences Centre), Yongjun Zhao(BC Cancer Agency), Allen Delaney(Canada's Michael Smith Genome Sciences Centre), Thomas Zeng(Canada's Michael Smith Genome Sciences Centre), Kane Tse(Canada's Michael Smith Genome Sciences Centre), Yaron S.N. Butterfield(Canada's Michael Smith Genome Sciences Centre), İnanç Birol(Canada's Michael Smith Genome Sciences Centre), Robert A. Holt(Canada's Michael Smith Genome Sciences Centre), Jacqueline E. Schein(BC Cancer Agency), Douglas E. Horsman(BC Cancer Agency), Richard A. Moore(BC Cancer Agency), Steven J.M. Jones(Canada's Michael Smith Genome Sciences Centre), Joseph M. Connors(BC Cancer Agency), Martin Hirst(Canada's Michael Smith Genome Sciences Centre), Randy D. Gascoyne(University of British Columbia), Marco A. Marra(BC Cancer Agency)
Nature
July 26, 2011
Cited by 1,602Open Access
Full Text

Abstract

Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) are the two most common non-Hodgkin lymphomas (NHLs). Here we sequenced tumour and matched normal DNA from 13 DLBCL cases and one FL case to identify genes with mutations in B-cell NHL. We analysed RNA-seq data from these and another 113 NHLs to identify genes with candidate mutations, and then re-sequenced tumour and matched normal DNA from these cases to confirm 109 genes with multiple somatic mutations. Genes with roles in histone modification were frequent targets of somatic mutation. For example, 32% of DLBCL and 89% of FL cases had somatic mutations in MLL2, which encodes a histone methyltransferase, and 11.4% and 13.4% of DLBCL and FL cases, respectively, had mutations in MEF2B, a calcium-regulated gene that cooperates with CREBBP and EP300 in acetylating histones. Our analysis suggests a previously unappreciated disruption of chromatin biology in lymphomagenesis. Despite being a focus of research activity for many years, the mutations driving the two most common non-Hodgkin lymphomas — follicular lymphoma and diffuse large B-cell lymphoma — have remained cryptic. Whole genome sequencing, combined with transcriptome analysis and further resequencing of candidate genes in additional tumours, now show that histone methyltransferases and acetylases are frequently affected by mutations in these tumours. This study suggests a previously unappreciated importance of chromatin biology in lymphomagenesis.


Related Papers